Glioma Prognostic Subtyping – Astrocytoma, Oligodendroglioma, Meningioma, and Glioblastoma using New miRNA Biomarker Panel
Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit
Malignant gliomas are extremely aggressive and lethal form of brain tumors. Despite considerable advances in surgery, radiotherapy and chemotherapy, the prognosis for patients with gliomas remains poor. Molecular markers for early detection are fundamental to develop targeted treatments and to improve the outcome for patients with glioma. microRNAs (miRNAs) are a group of small, endogenous, noncoding RNA molecules that regulate a wide spectrum of gene expression in a posttranscriptional manner. Altered expressions of miRNAs have been associated with various malignancies including brain tumors. As a promising therapeutic tool against malignant gliomas, miRNAs have attracted increasing attention in recent years. In situ hybridization (ISH) technique with variant probe design or signal amplification allows direct assessment of miRNA expression within formalin-fixed, paraffin-embedded (FFPE) tissue. By using this method, the miRNA expression pattern in FFPE tumor tissue has been explored in many tumors.
Super Sensitive Nucleic Acid (SSNA) miRNA probes:
BioGenex has developed proprietary Super Sensitive Nucleic Acid (SSNA) miRNA probes that enhance signals from intrinsically low populated miRNAs. The SSNA oligos are synthesized using specially designed bases to give super high melting temperatures. The high melting temperatures enable stringent washes at elevated temperatures to remove non-specific binding. BioGenex miRNA probes are dual-end labeled on 3’ and 5’ with five FAM molecules that amplify the signal, giving intense stains. The high-density fluorophore-labeled SSNA probes combined with the BioGenex Super Sensitive ™ Detection System aid in studying the lowly expressed miRNA populations and miRNA expression profiles to assess the physiological function of miRNA.
The miRNA expression profiles are used to assess the cancer type or conditions for the below types:
- Cancer of unknown primary
- Undifferentiated and poorly differentiated tumors
- Classification of cancer subtypes
- Grading and staging of cancer
BioGenex is pleased to launch four Super Sensitive Nucleic Acid microRNA in situ hybridization (SSNA miRNA ISH) probes for subtyping and grading of gliomas. BioGenex SSNA miRNA ISH probes give consistent, reproducible and reliable outcomes.
The ready-to-use BioGenex miRNA ISH probes efficiently detected miRNA expression pattern in FFPE brain tumor. This novel assay used 35 FFPE cases of different brain tumors (astrocytoma, oligodendroglioma, meningioma and glioblastoma) and 30 low-and high-grade gliomas. Consistent with the high throughput screening reports, miR-10b was downregulated and miR-21 was upregulated in high-grade gliomas. The study results demonstrate SSNA miRNA ISH probe can serve as a potential therapeutic target for interventions in high-grade gliomas. Furthermore, visualization of miRNA expression is an advantage of ISH-based techniques over the PCR and microarray-based detection that lacks spatial information.
Please click on above links to download Biomarker Panel and Application Note for glioma subtyping and grading.
BioGenex also has an extensive catalog of over 240 unique miRNA probes